Cargando…

Nonalcoholic Fatty Liver Disease After Pancreaticoduodenectomy for a Cancer Diagnosis

Purpose: Current literature reports increased incidence of postpancreaticoduodenectomy (PD) nonalcoholic fatty liver disease (NAFLD), a precursor for nonalcoholic steatohepatitis and cirrhosis. The incidence of and risk factors (RFs) for NAFLD in the PD population, however, are not well elucidated....

Descripción completa

Detalles Bibliográficos
Autores principales: McGhee-Jez, Amy E., Chervoneva, Inna, Yi, Misung, Ahuja, Amisha, Nahar, Ritu, Shah, Samik, Loh, Rebecca, Houtmann, Sarah, Shah, Rashesh, Yeo, Charles J., Lavu, Harish, Cohen, Steven J., Halegoua-DeMarzio, Dina, Basu Mallick, Atrayee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8175252/
https://www.ncbi.nlm.nih.gov/pubmed/34095739
http://dx.doi.org/10.1089/pancan.2020.0006
_version_ 1783703014701268992
author McGhee-Jez, Amy E.
Chervoneva, Inna
Yi, Misung
Ahuja, Amisha
Nahar, Ritu
Shah, Samik
Loh, Rebecca
Houtmann, Sarah
Shah, Rashesh
Yeo, Charles J.
Lavu, Harish
Cohen, Steven J.
Halegoua-DeMarzio, Dina
Basu Mallick, Atrayee
author_facet McGhee-Jez, Amy E.
Chervoneva, Inna
Yi, Misung
Ahuja, Amisha
Nahar, Ritu
Shah, Samik
Loh, Rebecca
Houtmann, Sarah
Shah, Rashesh
Yeo, Charles J.
Lavu, Harish
Cohen, Steven J.
Halegoua-DeMarzio, Dina
Basu Mallick, Atrayee
author_sort McGhee-Jez, Amy E.
collection PubMed
description Purpose: Current literature reports increased incidence of postpancreaticoduodenectomy (PD) nonalcoholic fatty liver disease (NAFLD), a precursor for nonalcoholic steatohepatitis and cirrhosis. The incidence of and risk factors (RFs) for NAFLD in the PD population, however, are not well elucidated. Methods: A cohort of 421 patients from a single institution who underwent PD for carcinoma and followed for at least 6 months were assessed retrospectively for age, gender, pathology, surgical complications (operative blood loss and length of stay [LOS]), comorbidities (diabetes, hypertension, hyperlipidemia, obesity), tobacco use, pre- and postoperative nutritional status (albumin and body mass index [BMI]), use of pancreatic enzyme replacement, and perioperative laboratory values (hemoglobin and liver function test). Cox proportional hazards model was used to examine these potential RFs as predictors of time to development of post-PD NAFLD. Results: Sixty (14.3%) patients developed post-PD NAFLD. Patients with NAFLD were younger (61.10 vs. 65.01 years old) and had higher preoperative BMI (28.92 vs. 26.61). Multivariate Cox proportional hazard model identified higher preoperative BMI, shorter postoperative LOS, and female gender as RFs for post-PD NAFLD. After excluding 12 patients with rare histology, there was a lower unadjusted hazard of developing NAFLD (p-value = 0.018) in the adenocarcinoma group than in the neuroendocrine and periampullary tumor groups. There was no statistically significant association between post-PD NAFLD and other characteristics. Conclusion: Female gender, higher preoperative BMI, and shorter LOS deserve closer monitoring for earlier detection and management of NAFLD.
format Online
Article
Text
id pubmed-8175252
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Mary Ann Liebert, Inc., publishers
record_format MEDLINE/PubMed
spelling pubmed-81752522021-06-04 Nonalcoholic Fatty Liver Disease After Pancreaticoduodenectomy for a Cancer Diagnosis McGhee-Jez, Amy E. Chervoneva, Inna Yi, Misung Ahuja, Amisha Nahar, Ritu Shah, Samik Loh, Rebecca Houtmann, Sarah Shah, Rashesh Yeo, Charles J. Lavu, Harish Cohen, Steven J. Halegoua-DeMarzio, Dina Basu Mallick, Atrayee J Pancreat Cancer Original Article Purpose: Current literature reports increased incidence of postpancreaticoduodenectomy (PD) nonalcoholic fatty liver disease (NAFLD), a precursor for nonalcoholic steatohepatitis and cirrhosis. The incidence of and risk factors (RFs) for NAFLD in the PD population, however, are not well elucidated. Methods: A cohort of 421 patients from a single institution who underwent PD for carcinoma and followed for at least 6 months were assessed retrospectively for age, gender, pathology, surgical complications (operative blood loss and length of stay [LOS]), comorbidities (diabetes, hypertension, hyperlipidemia, obesity), tobacco use, pre- and postoperative nutritional status (albumin and body mass index [BMI]), use of pancreatic enzyme replacement, and perioperative laboratory values (hemoglobin and liver function test). Cox proportional hazards model was used to examine these potential RFs as predictors of time to development of post-PD NAFLD. Results: Sixty (14.3%) patients developed post-PD NAFLD. Patients with NAFLD were younger (61.10 vs. 65.01 years old) and had higher preoperative BMI (28.92 vs. 26.61). Multivariate Cox proportional hazard model identified higher preoperative BMI, shorter postoperative LOS, and female gender as RFs for post-PD NAFLD. After excluding 12 patients with rare histology, there was a lower unadjusted hazard of developing NAFLD (p-value = 0.018) in the adenocarcinoma group than in the neuroendocrine and periampullary tumor groups. There was no statistically significant association between post-PD NAFLD and other characteristics. Conclusion: Female gender, higher preoperative BMI, and shorter LOS deserve closer monitoring for earlier detection and management of NAFLD. Mary Ann Liebert, Inc., publishers 2021-03-30 /pmc/articles/PMC8175252/ /pubmed/34095739 http://dx.doi.org/10.1089/pancan.2020.0006 Text en © Amy E. McGhee-Jez et al., 2021; Published by Mary Ann Liebert, Inc. https://creativecommons.org/licenses/by/4.0/This Open Access article is distributed under the terms of the Creative Commons License [CC-BY] (http://creativecommons.org/licenses/by/4.0 (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
McGhee-Jez, Amy E.
Chervoneva, Inna
Yi, Misung
Ahuja, Amisha
Nahar, Ritu
Shah, Samik
Loh, Rebecca
Houtmann, Sarah
Shah, Rashesh
Yeo, Charles J.
Lavu, Harish
Cohen, Steven J.
Halegoua-DeMarzio, Dina
Basu Mallick, Atrayee
Nonalcoholic Fatty Liver Disease After Pancreaticoduodenectomy for a Cancer Diagnosis
title Nonalcoholic Fatty Liver Disease After Pancreaticoduodenectomy for a Cancer Diagnosis
title_full Nonalcoholic Fatty Liver Disease After Pancreaticoduodenectomy for a Cancer Diagnosis
title_fullStr Nonalcoholic Fatty Liver Disease After Pancreaticoduodenectomy for a Cancer Diagnosis
title_full_unstemmed Nonalcoholic Fatty Liver Disease After Pancreaticoduodenectomy for a Cancer Diagnosis
title_short Nonalcoholic Fatty Liver Disease After Pancreaticoduodenectomy for a Cancer Diagnosis
title_sort nonalcoholic fatty liver disease after pancreaticoduodenectomy for a cancer diagnosis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8175252/
https://www.ncbi.nlm.nih.gov/pubmed/34095739
http://dx.doi.org/10.1089/pancan.2020.0006
work_keys_str_mv AT mcgheejezamye nonalcoholicfattyliverdiseaseafterpancreaticoduodenectomyforacancerdiagnosis
AT chervonevainna nonalcoholicfattyliverdiseaseafterpancreaticoduodenectomyforacancerdiagnosis
AT yimisung nonalcoholicfattyliverdiseaseafterpancreaticoduodenectomyforacancerdiagnosis
AT ahujaamisha nonalcoholicfattyliverdiseaseafterpancreaticoduodenectomyforacancerdiagnosis
AT naharritu nonalcoholicfattyliverdiseaseafterpancreaticoduodenectomyforacancerdiagnosis
AT shahsamik nonalcoholicfattyliverdiseaseafterpancreaticoduodenectomyforacancerdiagnosis
AT lohrebecca nonalcoholicfattyliverdiseaseafterpancreaticoduodenectomyforacancerdiagnosis
AT houtmannsarah nonalcoholicfattyliverdiseaseafterpancreaticoduodenectomyforacancerdiagnosis
AT shahrashesh nonalcoholicfattyliverdiseaseafterpancreaticoduodenectomyforacancerdiagnosis
AT yeocharlesj nonalcoholicfattyliverdiseaseafterpancreaticoduodenectomyforacancerdiagnosis
AT lavuharish nonalcoholicfattyliverdiseaseafterpancreaticoduodenectomyforacancerdiagnosis
AT cohenstevenj nonalcoholicfattyliverdiseaseafterpancreaticoduodenectomyforacancerdiagnosis
AT halegouademarziodina nonalcoholicfattyliverdiseaseafterpancreaticoduodenectomyforacancerdiagnosis
AT basumallickatrayee nonalcoholicfattyliverdiseaseafterpancreaticoduodenectomyforacancerdiagnosis